Skip to main content

Advertisement

SpringerLink
Log in

Reliability of Medicaid Claims Versus Medical Record Data

In a Cost Analysis of Palivizumab

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Palivizumab is one of the most costly paediatric medications for Medicaid and other health plans. It is uncertain whether the costs of palivizumab administration are justified in specific risk groups. Ongoing investigations of palivizumab require identification of reliable data sources.

Objective: To estimate the reliability between Medicaid paid claims data and medical records documentation in a cost analysis of palivizumab. Study design: A cross-sectional study of data reliability was performed within a cost analysis study of palivizumab in a cohort of at-risk patients during the US 2002/3 respiratory syncytial virus season. Exposure classification (to palivizumab prophylaxis) was compared using Medicaid claims and medical records data.

Methods: The study was performed in 28 widely dispersed paediatric medical practices serving North Carolina, USA Medicaid patients within the AccessCare/Community Care of North Carolina (CCNC) Program, an enhanced primary care case management programme. Patients were eligible if they were born between 1 March 2002 and 28 February 2003 at 32–35 weeks estimated gestational age, were enrolled in the North Carolina primary care case management Medicaid programme during the study period and were patients of the participating practices. Medicaid healthcare claims were obtained in December 2003 for services provided between October 2002 and May 2003. Medical records were abstracted by community-based case managers. Primary variables included frequency, dates and dose of palivizumab injections. The main outcomes measures were agreement in the number of palivizumab injections, dates of administration and doses of palivizumab between Medicaid paid claims and medical record data.

Results: Injection frequencies matched between medical record and Medicaid claims data for only 46.2% of study participants. Congruence in injection service dates occurred between data sources for only 1% of injections. Doses were similar between data sources for 81.9% of injections.

Conclusions: In Medicaid recipients receiving palivizumab injection, Medicaid claims data were inconsistent with medical records data. Use of multiple data sources and validation are recommended to identify temporal relationships between drug administration and endpoints of interest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Iezzoni LI. Using administrative data to study persons with disabilities. Milbank Q 2002; 80: 347–379

    Article  PubMed  Google Scholar 

  2. Quam L, Ellis LBM, Venus P, et al. Using claims data for epidemiologic research. Med Care 1993; 31: 498–507

    Article  PubMed  CAS  Google Scholar 

  3. Gherkin DC, Deyo RA, Volinn E, et al. Use of the International Classification of Diseases (ICD-9-CM) to identify hospitalizations for mechanical low back problems in administrative databases. Spine 1992; 17: 17–25

    Google Scholar 

  4. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol 1989; 42: 937–945

    Article  PubMed  CAS  Google Scholar 

  5. Lipowski EE, Wiederholt JB, Kreling DH, et al. Use of a Medicaid database to analyze pharmaceutical services in long-term-care facilities. Am J Hosp Pharm 1986; 43: 1467–1472

    PubMed  CAS  Google Scholar 

  6. Berkanovic E. An appraisal of Medicaid records as a data source. Med Care 1974; XII: 590–595

    Article  Google Scholar 

  7. Wang PS, Walker A, Tsuang M, et al. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol 2000; 53: 571–578

    Article  PubMed  CAS  Google Scholar 

  8. Steinwachs DM, Stuart ME, Scholle S, et al. A comparison of ambulatory Medicaid claims to medical records: a reliability assessment. Am J Med Qual 1998; 13: 63–69

    Article  PubMed  CAS  Google Scholar 

  9. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care 1976; 14: 166–172

    Article  PubMed  CAS  Google Scholar 

  10. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004; 57: 131–141

    Article  PubMed  Google Scholar 

  11. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837–849

    PubMed  CAS  Google Scholar 

  12. King MA, Purdie DM, Roberts MS. Matching prescription claims with medication data for nursing home residents: implications for prescriber feedback, drug utilization studies and selection of prescription claims database. J Clin Epidemiol 2001; 54: 202–209

    Article  PubMed  CAS  Google Scholar 

  13. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999–1009

    Article  PubMed  CAS  Google Scholar 

  14. McKenzie DA, Semradek J, McFarland BH, et al. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000; 53: 1248–1257

    Article  PubMed  CAS  Google Scholar 

  15. Sena MM, Pashko S. Drug utilization review using a Medicaid claims database. Clin Ther 1993; 15: 900–904

    PubMed  CAS  Google Scholar 

  16. Hennessy S, Bilker WB, Weber A, et al. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003; 12: 103–111

    Article  PubMed  Google Scholar 

  17. Grisso J A, Carson JL, Feldman HI, et al. Epidemiological pitfalls using Medicaid data in reproductive health research. J Matern Fetal Med 1997; 6: 230–236

    Article  PubMed  CAS  Google Scholar 

  18. Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care 2001; 39: 1188–1202

    Article  PubMed  CAS  Google Scholar 

  19. Raleigh (NC): North Carolina Division of Medical Assistance, 2005. (Data on file)

  20. Morrisville (NC): AccessCare, 2006 Jul 24. (Data on file)

  21. Medlmmune Annual Report 2005 [online]. Available from URL: http://www.medimmuni.com/ar/2005/financials/mda4.html [Accessed 2006 Aug 17]

  22. Wegner S, Jacobson Vann J, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program. Pediatrics 2004; 114 (6): 1612–1619

    Article  PubMed  Google Scholar 

  23. Viswanathan M, King VJ, Bordley C, et al. Management of bronchiolitis in infants and children. [Evidence support/technology assessment no. 69, AHRQ publication no. 03-E014]. Rockville (MD): US Department of Health and Human Services, Agency for Healthcare Research and Quality, 2003

    Google Scholar 

  24. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442–1446

    Article  Google Scholar 

  25. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: prevention of respiratory syncytial virus infections. Indications for the use of palivizumab and update on the use of RSV-IGIV (RE9839). Pediatrics 1998; 102: 1211–1216

    Article  Google Scholar 

  26. Hennekens CH, Buring JE. Epidemiology in medicine. Boston/Toronto: Little, Brown and Company, 1987

    Google Scholar 

  27. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981: 217–232

    Google Scholar 

  28. Landis JR, Koch GG. The measure of observer agreement for categorical data. Biometrics 1977; 33: 159–174

    Article  PubMed  CAS  Google Scholar 

  29. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998; 24 (4): 323–355

    Google Scholar 

  30. SAS/STAT software, version SAS® 9.1 (TS1M3) of the SAS System for Windows. Cary (NC): SAS Institute Inc., 2002–3

  31. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Sage University Paper series on quantitative applications in the social sciences, 07-095. Newbury Park (CA): Sage University, 1993

    Google Scholar 

  32. SAS Institute Inc. The JackBoot macro, 2000 [online]. Available from URL: http://ftp.sas.com/techsup/download/stat/jackboothtml [Accessed 2006 Aug 31]

  33. Farina D, Rodriguez SP, Bauer G, et al. Respiratory synctial virus prophylaxis: cost effective analysis in Argentina. Pediatr Infect Dis J 2002; 21 (4): 287–291

    Article  PubMed  Google Scholar 

  34. Lund BC, Chrischilles EA, Carter BL, et al. Development of a computer algorithm for defining an active drug list using an automated pharmacy database. J Clin Epidemiol 2003; 56: 802–806

    Article  PubMed  Google Scholar 

  35. Humphries KH, Rankin JM, Carere RG, et al. Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review? J Clin Epidemiol 2000; 53: 343–349

    Article  PubMed  CAS  Google Scholar 

  36. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114 (6): 1606–1611

    Article  PubMed  Google Scholar 

  37. Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002; 38 (4): 352–327

    Article  PubMed  CAS  Google Scholar 

  38. Schrand LM, Elliott JM, Ross MB. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001; 35 (10): 534–535

    Google Scholar 

  39. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier. Arch Pediatr Adolesc Med 2000; 154 (1): 55–61

    PubMed  CAS  Google Scholar 

  40. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000; 36 (5): 422–427

    Article  PubMed  CAS  Google Scholar 

  41. Lofland JH, Touch SM, O’Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000; 22 (11): 1357–1369

    Article  PubMed  CAS  Google Scholar 

  42. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104 (3): 419–427

    Article  PubMed  CAS  Google Scholar 

  43. Marchetti A, Lau H, Magar R, et al. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999; 21 (4): 752–766

    Article  PubMed  CAS  Google Scholar 

  44. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid’s high-risk children. Arch Pediatr Adolesc Med 2002; 156: 1251–1255

    PubMed  Google Scholar 

  45. Norris CM, Ghali WA, Knudtson ML, et al. Dealing with missing data in observational health care outcomes analyses. J Clin Epidemiol 2000; 53: 377–383

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Courtney Sanderson, Brian Leinwand and Jafar Abbas for providing project support, and Drs Alan Stiles, William Campbell, Patricia Byrns and Gordon Liu for their collaboration on the cost analysis. The authors also thank the practice staff, AccessCare case managers and regional project managers for assistance with data collection. No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. School of Nursing, University of North Carolina at Chapel Hill, 544 Carrington Hall, CB #7460, Chapel Hill, North Carolina, 27599-7460, USA

    Julie Jacobson Vanna

  2. AccessCare, Morrisville, North Carolina, USA

    John Feaganes & Steven Wegner

  3. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

    Steven Wegner

Authors
  1. Julie Jacobson Vanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Feaganes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie Jacobson Vanna.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vanna, J.J., Feaganes, J. & Wegner, S. Reliability of Medicaid Claims Versus Medical Record Data. Pharmacoeconomics 25, 793–800 (2007). https://doi.org/10.2165/00019053-200725090-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725090-00007

Keywords

Search

Navigation